Nicholas T Funderburg

List of Publications by Year
in descending order

116 papers	6,197 citations	76326 40 h-index	74163 75 g-index
164 all docs	164 docs citations	164 times ranked	7813 citing authors

#	Article	IF	Citations
1	Impact of Heroin and HIV on Gut Integrity and Immune Activation. Journal of Acquired Immune Deficiency Syndromes (1999), 2022, Publish Ahead of Print, .	2.1	7
2	Sexual minorities are at elevated risk of cardiovascular disease from a younger age than heterosexuals. Journal of Behavioral Medicine, 2022, 45, 571-579.	2.1	12
3	Lipidome Alterations with Exercise Among People With and Without HIV: An Exploratory Study. AIDS Research and Human Retroviruses, 2022, 38, 544-551.	1.1	2
4	A Pilot Study Comparing Aortic Sonography, Flow Cytometry, and Coronary CT.. Radiologic Technology, 2022, 93, 454-461.	0.1	0
5	Estrogen May Enhance Toll-Like Receptor 4-Induced Inflammatory Pathways in People With HIV: Implications for Transgender Women on Hormone Therapy. Frontiers in Immunology, 2022, 13, .	4.8	1
6	Levels of Soluble CD14 and Tumor Necrosis Factor Receptors 1 and 2 May Be Predictive of Death in Severe Coronavirus Disease 2019. Journal of Infectious Diseases, 2021, 223, 805-810.	4.0	27
7	Lipidome association with vascular disease and inflammation in HIV+ Ugandan children. Aids, 2021, 35, 1615-1623.	2.2	6
8	Changes in lipidomic profile by anti-retroviral treatment regimen. Medicine (United States), 2021, 100, e26588.	1.0	1
9	Chronic cannabis smoking-enriched oral pathobiont drives behavioral changes, macrophage infiltration, and increases Î²-amyloid protein production in the brain. EBioMedicine, 2021, 74, 103701.	6.1	8
10	Editorial: Infectious Agent-Induced Chronic Immune Activation: Causes, Phenotypes, and Consequences. Frontiers in Immunology, 2021, 12, 740556.	4.8	1
11	Altered Intestinal Permeability and Fungal Translocation in Ugandan Children With Human Immunodeficiency Virus. Clinical Infectious Diseases, 2020, 70, 2413-2422.	5.8	26
12	Highly oxidized lowâ€density lipoprotein mediates activation of monocytes but does not confer interleukinâ€1 Î² secretion nor interleukinâ€15 transpresentation function. Immunology, 2020, 159, 221-230.	4.4	3
13	Insulin resistance and intestinal integrity in children with and without HIV infection in Uganda. HIV Medicine, 2020, 21, 119-127.	2.2	13
14	Subclinical Vascular Disease in Children With Human Immunodeficiency Virus in Uganda Is Associated With Intestinal Barrier Dysfunction. Clinical Infectious Diseases, 2020, 71, 3025-3032.	5.8	13
15	In VitroExposure of Leukocytes to HIV Preexposure Prophylaxis Decreases Mitochondrial Function and Alters Gene Expression Profiles. Antimicrobial Agents and Chemotherapy, 2020, 65, .	3.2	8
16	Macrophage maturation from blood monocytes is altered in people with HIV, and is linked to serum lipid profiles and activation indices: A model for studying atherogenic mechanisms. PLoS Pathogens, 2020, 16, e1008869.	4.7	21
17	CX3CL1 and IL-15 Promote CD8 T cell chemoattraction in HIV and in atherosclerosis. PLoS Pathogens, 2020, 16, e1008885.	4.7	17
18	Innate Immune Responses to Highly Pathogenic Coronaviruses and Other Significant Respiratory Viral Infections. Frontiers in Immunology, 2020, 11, 1979.	4.8	25

#	Article	IF	Citations
19	PLATELET AND MONOCYTE ACTIVATION AFTER TRANSCATHETER AORTIC VALVE REPLACEMENT (POTENT-TAVR): A RANDOMIZED CONTROLLED TRIAL OF TICAGRELOR VERSUS CLOPIDOGREL BEFORE TAVR. Journal of the American College of Cardiology, 2020, 75, 1470.	2.8	0
20	Plasma lipidome abnormalities in people with HIV initiating antiretroviral therapy. Translational Medicine Communications, 2020, 5, .	1.4	1
21	Micronutrients, Metabolic Complications, and Inflammation in Ugandan Children With HIV. Journal of Pediatric Gastroenterology and Nutrition, 2020, 70, e100-e105.	1.8	7
22	Immunomodulatory and Anti-Inflammatory Strategies to Reduce Comorbidity Risk in People with HIV. Current HIV/AIDS Reports, 2020, 17, 394-404.	3.1	11
23	Relationship between economic insecurity, inflammation, monocyte activation and intestinal integrity in children living with HIV in Uganda. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2020, 32, 1451-1456.	1.2	4
24	Increased monocyte and T-cell activation in treated HIV+ Ugandan children: associations with gut alteration and HIV factors. Aids, 2020, 34, 1009-1018.	2.2	14
25	Cytomegalovirus Coinfection Is Associated with Increased Vascular-Homing CD57+ CD4 T Cells in HIV Infection. Journal of Immunology, 2020, 204, 2722-2733.	0.8	23
26	"Inflammescent" CX3CR1+CD57+ CD8 T cells are generated and expanded by IL-15. JCI Insight, 2020, 5, .	5.0	18
27	Pathogenesis of Aging and Age-related Comorbidities in People with HIV: Highlights from the HIV ACTION Workshop. Pathogens and Immunity, 2020, 5, 143.	3.1	42
28	Altered Lipidome Composition Is Related to Markers of Monocyte and Immune Activation in Antiretroviral Therapy Treated Human Immunodeficiency Virus (HIV) Infection and in Uninfected Persons. Frontiers in Immunology, 2019, 10, 785.	4.8	34
29	Harvard HIV and Aging Workshop: Perspectives and Priorities from Claude D. Pepper Centers and Centers for AIDS Research. AIDS Research and Human Retroviruses, 2019, 35, 999-1012.	1.1	12
30	CD8+ T-Cellâ€“Derived Tumor Necrosis Factor Can Induce Tissue Factor Expression on Monocytes. Journal of Infectious Diseases, 2019, 220, 73-77.	4.0	14
31	Lipidome Abnormalities and Cardiovascular Disease Risk in HIV Infection. Current HIV/AIDS Reports, 2019, 16, 214-223.	3.1	19
32	Fungal Translocation Is Associated with Immune Activation and Systemic Inflammation in Treated HIV. AIDS Research and Human Retroviruses, 2019, 35, 461-472.	1.1	26
33	HIV-exposed-uninfected infants have increased inflammation and monocyte activation. Aids, 2019, 33, 845-853.	2.2	54
34	2528. Inflammation and Plasma Selenium and Chromium in Ugandan Children Living with HIV. Open Forum Infectious Diseases, 2019, 6, S879-S879.	0.9	0
35	Changes in the Fungal Marker Î²-D-Glucan After Antiretroviral Therapy and Association With Adiposity. Open Forum Infectious Diseases, 2019, 6, ofz434.	0.9	15
36	Brief Report: Zinc Supplementation and Inflammation in Treated HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 82, 275-280.	2.1	10

#	Article	IF	Citations
37	Soluble Urokinase Plasminogen Activator Receptor Is Predictive of Non-AIDS Events During Antiretroviral Therapyâ€“mediated Viral Suppression. Clinical Infectious Diseases, 2019, 69, 676-686.	5.8	49
38	Statin Therapy Does Not Reduce Liver Fat Scores in Patients Receiving Antiretroviral Therapy for HIV Infection. Clinical Gastroenterology and Hepatology, 2019, 17, 536-542.e1.	4.4	8
39	Heavy Cannabis Use Associated With Reduction in Activated and Inflammatory Immune Cell Frequencies in Antiretroviral Therapyâ€“Treated Human Immunodeficiency Virusâ€“Infected Individuals. Clinical Infectious Diseases, 2018, 66, 1872-1882.	5.8	85
40	Serum Albumin Is Associated With Higher Inflammation and Carotid Atherosclerosis in Treated Human Immunodeficiency Virus Infection. Open Forum Infectious Diseases, 2018, 5, ofy291.	0.9	15
41	933. Serum Albumin Is Associated With Higher Inflammation and Carotid Atherosclerosis in Treated HIV Infection. Open Forum Infectious Diseases, 2018, 5, S32-S32.	0.9	0
42	937. Virally Suppressed PLH Switching From Abacavir to Tenofovir Alafenamide Did Not Have Changes in Immune Activation or Inflammation. Open Forum Infectious Diseases, 2018, 5, S34-S34.	0.9	0
43	Anisocytosis and leukocytosis are independently related to survival after transcatheter aortic valve replacement. Journal of Cardiovascular Medicine, 2018, 19, 191-194.	1.5	2
44	Transcriptional Profiling Identifies Mechanisms Associated With Platelet Activation in HIV Infection. JACC Basic To Translational Science, 2018, 3, 23-24.	4.1	0
45	CD56bright NK IL-7RÎ± expression negatively associates with HCV level, and IL-7-induced NK function is impaired during HCV and HIV infections. Journal of Leukocyte Biology, 2017, 102, 171-184.	3.3	18
46	Inflammation, Immune Activation, and Antiretroviral Therapy in HIV. Current HIV/AIDS Reports, 2017, 14, 93-100.	3.1	170
47	Alcohol and dietary factors associate with gut integrity and inflammation in <scp>HIV</scp>â€infected adults. HIV Medicine, 2017, 18, 402-411.	2.2	22
48	Comprehensive assessment of the arginine pathway and its relationship to inflammation in HIV. Aids, 2017, 31, 533-537.	2.2	6
49	HIV-positive youth who are perinatally infected have impaired endothelial function. Aids, 2017, 31, 1917-1924.	2.2	29
50	Brief Report: Elevated Red Cell Distribution Width Identifies Elevated Cardiovascular Disease Risk in Patients With HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 74, 298-302.	2.1	17
51	Effect of statin on arginine metabolites in treated HIV-infection. Atherosclerosis, 2017, 266, 74-80.	0.8	4
52	Soluble TWEAK may predict carotid atherosclerosis in treated HIV infection. HIV Clinical Trials, 2017, 18, 156-163.	2.0	10
53	Effects of atorvastatin on biomarkers of immune activation, inflammation, and lipids in virologically suppressed, human immunodeficiency virus-1â€“infected individuals with low-density lipoprotein cholesterol <130Âmg/dL (AIDS Clinical Trials Group Study A5275). Journal of Clinical Lipidology, 2017, 11, 61-69.	1.5	27
54	A Randomized Placebo Controlled Trial of Aspirin Effects on Immune Activation in Chronically Human Immunodeficiency Virus-Infected Adults on Virologically Suppressive Antiretroviral Therapy. Open Forum Infectious Diseases, 2017, 4, ofw278.	0.9	58

#	Article	IF	Citations
55	Cellular fatty acid synthase is required for late stages of HIV-1 replication. Retrovirology, 2017, 14, 45.	2.0	36
56	Prospective Analysis of Lipid Composition Changes with Antiretroviral Therapy and Immune Activation in Persons Living with HIV. Pathogens and Immunity, 2017, 2, 376.	3.1	36
57	Rosuvastatin Decreases Intestinal Fatty Acid Binding Protein (I-FABP), but does not Alter Zonulin or Lipopolysaccharide Binding Protein (LBP) Levels, in HIV-Infected Subjects on Antiretroviral Therapy. Pathogens and Immunity, 2016, 1, 118.	3.1	13
58	Equivalent Decline in Inflammation Markers with Tenofovir Disoproxil Fumarate vs. Tenofovir Alafenamide. EBioMedicine, 2016, 13, 321-327.	6.1	16
59	Altered Monocyte and Endothelial Cell Adhesion Molecule Expression Is Linked to Vascular Inflammation in Human Immunodeficiency Virus Infection. Open Forum Infectious Diseases, 2016, 3, ofw224.	0.9	41
60	Identification of Immune Activation Profiles That May Predict Morbidity During Antiretroviral Therapy Treated HIV Infection. EBioMedicine, 2016, 8, 16-17.	6.1	1
61	Inflammatory Function of CX3CR1⁺CD8⁺T Cells in Treated HIV Infection Is Modulated by Platelet Interactions. Journal of Infectious Diseases, 2016, 214, 1808-1816.	4.0	35
62	High levels of self-reported prescription opioid use by HIV-positive individuals. AIDS Care - Psychological and Socio-Medical Aspects of AIDS/HIV, 2016, 28, 1559-1565.	1.2	16
63	Brief Report: CD14brightCD16â˜ monocytes and sCD14 level negatively associate with CD4-memory T-cell frequency and predict HCV-decline on therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 73, 258-262.	2.1	5
64	Treatment of HIV infection with a raltegravir-based regimen increases LDL levels, but improves HDL cholesterol efflux capacity. Antiviral Therapy, 2016, 22, 71-75.	1.0	11
65	Inflammation Perturbs the IL-7 Axis, Promoting Senescence and Exhaustion that Broadly Characterize Immune Failure in Treated HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, 483-492.	2.1	59
66	Lipid Abnormalities and Inflammation in HIV Inflection. Current HIV/AIDS Reports, 2016, 13, 218-225.	3.1	100
67	SIV/SHIV Infection Triggers Vascular Inflammation, Diminished Expression of KrÃ¼ppel-like Factor 2 and Endothelial Dysfunction. Journal of Infectious Diseases, 2016, 213, 1419-1427.	4.0	20
68	Altered Maturation Status and Possible Immune Exhaustion of CD8 T Lymphocytes in the Peripheral Blood of Patients Presenting With Acute Coronary Syndromes. Arteriosclerosis, Thrombosis, and Vascular Biology, 2016, 36, 389-397.	2.4	14
69	Changes in oxidized lipids drive the improvement in monocyte activation and vascular disease after statin therapy in HIV. Aids, 2016, 30, 65-73.	2.2	49
70	Oxidized LDL Levels Are Increased in HIV Infection and May Drive Monocyte Activation. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 69, 154-160.	2.1	85
71	Anaemia is Associated with Monocyte Activation in HIV-Infected Adults on Antiretroviral Therapy. Antiviral Therapy, 2015, 20, 521-527.	1.0	6
72	Altered Monocyte Phenotype in HIV-1 Infection Tends to Normalize with Integrase-Inhibitor-Based Antiretroviral Therapy. PLoS ONE, 2015, 10, e0139474.	2.5	25

#	Article	IF	Citations
73	Rosuvastatin Reduces Vascular Inflammation and T-cell and Monocyte Activation in HIV-Infected Subjects on Antiretroviral Therapy. Journal of Acquired Immune Deficiency Syndromes (1999), 2015, 68, 396-404.	2.1	135
74	Lipopolysaccharide and soluble CD14 in cord blood plasma are associated with prematurity and chorioamnionitis. Pediatric Research, 2014, 75, 67-74.	2.3	28
75	Gut Epithelial Barrier Dysfunction and Innate Immune Activation Predict Mortality in Treated HIV Infection. Journal of Infectious Diseases, 2014, 210, 1228-1238.	4.0	395
76	Progressive Proximal-to-Distal Reduction in Expression of the Tight Junction Complex in Colonic Epithelium of Virally-Suppressed HIV+ Individuals. PLoS Pathogens, 2014, 10, e1004198.	4.7	61
77	Markers of coagulation and inflammation often remain elevated in ART-treated HIV-infected patients. Current Opinion in HIV and AIDS, 2014, 9, 80-86.	3.8	82
78	Soluble CD14 is independently associated with coronary calcification and extent of subclinical vascular disease in treated HIV infection. Aids, 2014, 28, 969-977.	2.2	121
79	Plasmacytoid Dendritic Cells Mediate Synergistic Effects of HIV and Lipopolysaccharide on CD27⁺IgD^{â€“}Memory B Cell Apoptosis. Journal of Virology, 2014, 88, 11430-11441.	3.4	14
80	Rosuvastatin Treatment Reduces Markers of Monocyte Activation in HIV-Infected Subjects on Antiretroviral Therapy. Clinical Infectious Diseases, 2014, 58, 588-595.	5.8	125
81	Sevelamer Does Not Decrease Lipopolysaccharide or Soluble CD14 Levels But Decreases Soluble Tissue Factor, Low-Density Lipoprotein (LDL) Cholesterol, and Oxidized LDL Cholesterol Levels in Individuals With Untreated HIV Infection. Journal of Infectious Diseases, 2014, 210, 1549-1554.	4.0	80
82	Effect of 24 Weeks of Statin Therapy on Systemic and Vascular Inflammation in HIV-Infected Subjects Receiving Antiretroviral Therapy. Journal of Infectious Diseases, 2014, 209, 1156-1164.	4.0	105
83	Inflammatory Cytokines Drive CD4+ T-Cell Cycling and Impaired Responsiveness to Interleukin 7: Implications for Immune Failure in HIV Disease. Journal of Infectious Diseases, 2014, 210, 619-629.	4.0	77
84	Rosuvastatin Preserves Renal Function and Lowers Cystatin C in HIV-Infected Subjects on Antiretroviral Therapy: The SATURN-HIV Trial. Clinical Infectious Diseases, 2014, 59, 1148-1156.	5.8	39
85	Cycling Memory CD4⁺T Cells in HIV Disease Have a Diverse T Cell Receptor Repertoire and a Phenotype Consistent with Bystander Activation. Journal of Virology, 2014, 88, 5369-5380.	3.4	24
86	Coagulation and morbidity in treated HIV infection. Thrombosis Research, 2014, 133, S21-S24.	1.7	45
87	Alterations in Regulatory T Cell Subpopulations Seen in Preterm Infants. PLoS ONE, 2014, 9, e95867.	2.5	42
88	Residual Immune Dysregulation Syndrome in Treated HIV infection. Advances in Immunology, 2013, 119, 51-83.	2.2	295
89	Circulating <scp>CD</scp>4⁺ and <scp>CD</scp>8⁺ T cells are activated in inflammatory bowel disease and are associated with plasma markers of inflammation. Immunology, 2013, 140, 87-97.	4.4	124
90	Markers of inflammation and <scp>CD8 T</scp>â€cell activation, but not monocyte activation, are associated with subclinical carotid artery disease in <scp>HIV</scp>â€infected individuals. HIV Medicine, 2013, 14, 385-390.	2.2	107

#	Article	IF	Citations
91	Human Î² defensinâ€3 induces chemokines from monocytes and macrophages: diminished activity in cells from <scp>HIV</scp>â€infected persons. Immunology, 2013, 140, 413-420.	4.4	30
92	Perivascular fat, inflammation, and cardiovascular risk in HIV-infected patients on antiretroviral therapy. International Journal of Cardiology, 2013, 168, 4039-4045.	1.7	44
93	Microbial translocation, immune activation, and HIV disease. Trends in Microbiology, 2013, 21, 6-13.	7.7	289
94	Systemic Immune Activation and Microbial Translocation in Dual HIV/Tuberculosis-Infected Subjects. Journal of Infectious Diseases, 2013, 207, 1841-1849.	4.0	21
95	The immunologic effects of maraviroc intensification in treated HIV-infected individuals with incomplete CD4+ T-cell recovery: a randomized trial. Blood, 2013, 121, 4635-4646.	1.4	117
96	Plasma Proteome Analysis Reveals Overlapping, yet Distinct Mechanisms of Immune Activation in Chronic HCV and HIV Infections. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, 563-571.	2.1	15
97	Interferon-Î± Is the Primary Plasma Type-I IFN in HIV-1 Infection and Correlates with Immune Activation and Disease Markers. PLoS ONE, 2013, 8, e56527.	2.5	146
98	Probiotic/prebiotic supplementation of antiretrovirals improves gastrointestinal immunity in SIV-infected macaques. Journal of Clinical Investigation, 2013, 123, 903-7.	8.2	135
99	Decreased IL-7 Responsiveness Is Related to Oxidative Stress in HIV Disease. PLoS ONE, 2013, 8, e58764.	2.5	26
100	Dynamics of Immune Reconstitution and Activation Markers in HIV+ Treatment-NaÃ¯ve Patients Treated with Raltegravir, Tenofovir Disoproxil Fumarate and Emtricitabine. PLoS ONE, 2013, 8, e83514.	2.5	45
101	Magnesium Decreases Inflammatory Cytokine Production: A Novel Innate Immunomodulatory Mechanism. Journal of Immunology, 2012, 188, 6338-6346.	0.8	276
102	Membrane damage and repair in primary monocytes exposed to human Î²-defensin-3. Journal of Leukocyte Biology, 2012, 92, 1083-1091.	3.3	20
103	Increased Platelet and Microparticle Activation in HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, 340-346.	2.1	131
104	HIV-1 Is Not a Major Driver of Increased Plasma IL-6 Levels in Chronic HIV-1 Disease. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 61, 145-152.	2.1	30
105	Shared monocyte subset phenotypes in HIV-1 infection and in uninfected subjects with acute coronary syndrome. Blood, 2012, 120, 4599-4608.	1.4	188
106	Diminished responsiveness to human Î²-defensin-3 and decreased TLR1 expression on monocytes and mDCs from HIV-1-infected patients. Journal of Leukocyte Biology, 2012, 92, 1103-1109.	3.3	8
107	Interferon-Alpha Administration Enhances CD8+ T Cell Activation in HIV Infection. PLoS ONE, 2012, 7, e30306.	2.5	42
108	The Toll-like receptor 1/2 agonists Pam3CSK4 and human Î²-defensin-3 differentially induce interleukin-10 and nuclear factor-ÎºB signalling patterns in human monocytes. Immunology, 2011, 134, 151-160.	4.4	72

#	Article	IF	Citations
109	Frequencies of FoxP3+ naÃ¯ve T cells are related to both viral load and naÃ¯ve T cell proliferation responses in HIV disease. Journal of Leukocyte Biology, 2011, 90, 621-628.	3.3	4
110	Immunologic Failure Despite Suppressive Antiretroviral Therapy Is Related to Activation and Turnover of Memory CD4 Cells. Journal of Infectious Diseases, 2011, 204, 1217-1226.	4.0	265
111	Increased tissue factor expression on circulating monocytes in chronic HIV infection: relationship to in vivo coagulation and immune activation. Blood, 2010, 115, 161-167.	1.4	241
112	Effects of Maraviroc and Efavirenz on Markers of Immune Activation and Inflammation and Associations with CD4+ Cell Rises in HIV-Infected Patients. PLoS ONE, 2010, 5, e13188.	2.5	76
113	Toll-Like Receptor Ligands Induce Human T Cell Activation and Death, a Model for HIV Pathogenesis. PLoS ONE, 2008, 3, e1915.	2.5	120
114	Human Î²-defensin-3 activates professional antigen-presenting cells via Toll-like receptors 1 and 2. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 18631-18635.	7.1	321
115	Genetic Analysis of Developmentally Regulated Resistance to Downy Mildew (Hyaloperonospora) Tj ETQq1 1 0.784314 rgBT /Overloc	2.6	53
116	SARS-CoV-2 Survivors With Chronic Health Conditions: A Pilot Study on â€œCOVID Long-Haulersâ€• Journal of Diagnostic Medical Sonography, 0, , 875647932211002.	0.3	0